




HEOR and Medical Access



# Health Economics & Outcomes Research and Medical Access Fellowships

2023-2025



# Novartis is a world leader in the research and development of products to protect and improve health and well-being.

Novartis was created in 1996 from the merger of the Swiss companies Ciba-Geigy and Sandoz. Novartis Pharmaceuticals is dedicated to discovering, developing, manufacturing, and marketing prescription drugs to prevent and cure diseases, to ease suffering and to enhance quality of life. Novartis' portfolio of products is directed toward cardiovascular, multiple sclerosis, immunology, hepatology, and dermatology, organ transplantation, ophthalmology, oncology and hematology, and other therapeutic areas.

Novartis, derived from the Latin *novae artes*, meaning "new skills," is committed to using new skills to improve health and well-being through innovative products and services. Recognizing an increasing need for outcomes information, resources and expertise, the Health Economics & Outcomes Research (HEOR) departments at Novartis strive to be best-in-class in the generation of outcomes evidence that demonstrates value and optimizes patient access to Novartis products. This is accomplished through execution of burden

and cost-of-illness studies, economic evaluations alongside clinical trials, comparative effectiveness research, cost-effectiveness analyses, prospective observational studies such as effectiveness registries, retrospective claims database analyses and patient-reported outcomes research.



## Purpose

The Health Economics & Outcomes Research (HEOR) and Medical Access Fellowship Program provides training and hands-on experience in a broad range of health economics, outcomes research and comparative effectiveness research (CER) opportunities. This 2-year program is structured to allow the Fellows to gain proficiency in the field of health economics, outcomes research and CER as conducted in academic, managed care, hospital, health policy and/or pharmaceutical industry settings.



## Overview

Novartis Pharmaceuticals Corporation is pleased to offer four 2-year Health Economics & Outcomes Research (HEOR) and Medical Access Fellowship positions for the 2023-2025 cycle.

The objective of the first year is to educate the fellow on general principles and methods applied in health economics and outcomes research. Concurrently, the fellow will participate in ongoing outcomes research projects at the first year fellowship site. All Fellows will spend the second year of the Fellowship at the US-based headquarters of Novartis Pharmaceuticals Corporation located in East Hanover, New Jersey.

While at Novartis, "field-based" training will be undertaken as part of the Fellowship training. Fellows will participate in health economics and outcomes research projects and gain experience in how a pharmaceutical manufacturer uses clinical, economic, and humanistic data to support the development and commercialization of its products, with opportunities in neuroscience, respiratory, ophthalmology, immunology, dermatology, cardiovascular, and transplant franchises.


In addition, a unique 3-6 month rotational opportunity will also be available in Medical Access, where the fellow will gain experience in "value translation" to national and regional payer accounts. The fellow will help identify strategic trends in the external payer and health plan environment that may impact access to and reimbursement for Novartis' products.

The fellowship positions differ by first-year site requirements and type of experience offered. Each position is described in this brochure. Compensation includes a competitive stipend, basic medical insurance, holiday and vacation time, plus other benefits associated with each specific academic/managed care institution.

## First-Year Fellowship Sites for 2-Year Programs (4 Positions):

- Baylor Scott & White Health, Temple, TX/  
The University of Texas at Austin, Austin, TX (2 positions)
- Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA (2 positions)
- Department of Pharmaceutical Health Services Research, University of Maryland, Baltimore, MD (not recruiting 2023-2025)

## Fellowship Alumni: Where Are They Now?



## Contact

Please contact current Fellows for any site-specific questions (contact information provided on subsequent pages).

For inquiries regarding general application or interview process, please contact:

Batul Electricwala, PhD, BPharm  
Director, HE&OR and  
HE&OR Fellowship Director  
East Hanover, NJ  
batul.electricwala@novartis.com



# Novartis Pharmaceuticals Corporation/ Baylor Scott & White Health/ The University of Texas at Austin



## Fellowship Sites & Preceptors

### Baylor Scott & White Health

Paul Godley, PharmD, FASHP, BCPS, Director of Pharmacy, Ambulatory & Speciality Clinical Pharmacy Services, Temple, TX

### The University of Texas at Austin College of Pharmacy

Karen Rascati, RPh, PhD, FAPhA, Graduate Advisor, Eckerd/Turley Centennial Endowed Professor, Austin, TX

### Novartis Pharmaceuticals Corporation

Batul Electricwala, PhD, BPharm, Director, HE&OR and HE&OR Fellowship Director, East Hanover, NJ

## Baylor Scott & White Health/The University of Texas

Baylor Scott & White is an integrated healthcare system in central Texas. The Scott & White Health Plan is a health maintenance organization that has over 400,000 members and is affiliated with the Baylor Scott & White Quality Alliance, the system's accountable care organization, which represents over 6,000 physicians. Baylor Scott & White is affiliated with the College of Medicine, Texas A&M University Health Science Center, and the College of Pharmacy, The University of Texas at Austin.

The Department of Pharmacy at Baylor Scott & White provides progressive and innovative pharmaceutical services in a variety of environments for all components of the institution. Included are clinical and distributive services for the hospital, clinic and health plan, as well as sponsorship of pharmaceutical care programs and ambulatory care clinics focusing on lipid, diabetes and anticoagulation management. Fellows will gain significant understanding of the key issues involved in pharmacy services provided by prescription benefits management and managed care organizations. The integrated character of the institution and the Department of Pharmacy provides significant opportunities for pharmacy practice, research and education.

The Health Outcomes and Pharmacy Practice Division, College of Pharmacy, The University of Texas at Austin, is one of the preeminent educational institutions for pharmacy education in the nation. The college is located in

downtown Austin, and the Fellow is offered the option of pursuing the Master of Science degree in Pharmaceutical Sciences at the University of Texas, Austin. The degree would be granted at the end of the Fellowship provided that the required coursework and thesis have been completed. The recommended course of study is designed to assist the Fellow in coordinating required and recommended coursework along with the Fellowship requirements. However, the coursework is tailored based on individual interests, background and career goals. Additionally, the College is home to TxCORE (Texas Center for Health Outcomes Research and Education), which is a leader in addressing population and individual health through innovative, high-quality research, and education, and serves the community by responding to critical health care issues that impact patients' daily lives. TxCORE combines the strengths of its nationally recognized clinical, pharmacy, social and behavioral, economics, and policy researchers to collect, analyze, and interpret data, and disseminate research findings throughout the many sectors of the health care industry, government, and private sector organizations.

The unique nature of the Baylor Scott & White integrated healthcare system, combined with the pharmacoeconomic expertise at the College of Pharmacy, offers significant opportunity for individuals interested in the Novartis Fellowship experience.

### Eligibility

*Eligible candidates must have a doctorate in pharmacy or the combination of an undergraduate degree in pharmacy plus an advanced degree in health services research, public health, health policy, pharmacy, economics, medicine or other related area. Experience in, or at a minimum, exposure to some aspect of outcomes research, health economics or another related field of research is preferred.*

### Information

*For questions or additional information, please contact:*

Karishma Thakkar, PharmD  
Health Economics & Outcomes Research and  
Medical Access Fellow  
Email: Karishma.Thakkar@BSWHealth.org

All questions regarding potential visa sponsorship should be directed to the collaborating institution.



**First-Year Fellow:  
Karishma Thakkar, PharmD**

Karishma Thakkar is a first-year Health Economics & Outcomes Research (HEOR) and Medical Access Fellow with Novartis Pharmaceuticals Corporation, Baylor Scott & White Health (BSWH), and the University of Texas at Austin.

Karishma received her Doctor of Pharmacy degree from the University of Houston College of Pharmacy. Her passion in health economics and outcomes research stemmed from her involvement in the AMCP P&T competition and IPhO VIP Case Competition. She enters the Fellowship with her background in research, managed care, hospital, and specialty pharmacy.

During her time in pharmacy school, Karishma conducted a systematic literature review and worked on quality improvement projects to decrease hospital readmission rates. This allowed her to gain hands-on experience in formulating search strategies, designing data extraction protocols, and analyzing results. She also worked for a health plan, where she supported the Director of Pharmacy in strategizing ways to improve key accountable care organization metrics and health outcomes for their members. Lastly, she completed a rotation at a specialty and medication access pharmacy in which she collaborated with manufacturers such as Eli Lilly, Novo Nordisk, and Genentech to provide financial assistance to uninsured patients.

During her first year, Karishma collaborates with pharmaceutical companies to conduct implementation science studies at BSWH, while supporting the Antimicrobial Stewardship and the P&T Committee. Her current projects include outcomes research surrounding an increase in diabetic drug spend and trending antimicrobial usage to guide clinical decisions at BSWH. In addition, Karishma is working towards earning a Master's degree in Pharmaceutical Science from the Division of Health Outcomes and Pharmacy Practice at the University of Texas at Austin.



**Second-Year Fellow:  
Ryan Thaliffdeen, PharmD**

Ryan Thaliffdeen is the second-year Health Economics & Outcomes Research (HEOR) Fellow with Novartis Pharmaceuticals Corporation, Baylor Scott & White Health (BSWH), and the University of Texas at Austin (UT Austin). Ryan received his Doctor of Pharmacy degree from the University of California, San Francisco (UCSF). During his time at UCSF, Ryan developed patient-reported outcomes disease area strategies and conceptual models as a Patient-Centered Outcomes Research intern at Genentech. In addition to industry, Ryan has a background in outcomes research from his role at UCSF's Medication Outcomes Center, where he investigated real-world outcomes of CAR T-Cell Therapy Yescarta® (axicabtagene ciloleucel). Other relevant experiences include acting as president for the UCSF-AMCP chapter, a Global HEOR internship at AMCP/Allergan, and HEOR consulting at Coeus consulting group.

During his first year at BSWH and UT Austin, Ryan led an industry-sponsored study in collaboration with BSWH to examine outcomes of patients with venous thromboembolism. He was also able to support a variety of internal research committees such as an antimicrobial stewardship committee and specialty task force, utilizing electronic health record and retrospective claims data. Some of his projects included an analysis of key performance indicators in the BSWH commercial and Medicare populations, a budget impact analysis of alteplase vs. tenecteplase for stroke, and assessment of antibiotic prescribing trends to drive operational decisions at BSWH. Ryan also supported various projects at UT Austin including a claims analysis of prostate cancer patients comorbid with heart failure, a cost-effectiveness analysis in migraine, and a systematic literature review of the use of machine learning to predict outcomes in patients with bladder cancer. As a result, Ryan has presented 8 posters at various conferences including ASHP midyear, AMCP Annual, and ISPOR and is in the process of publishing 3 manuscripts.

In his second year at Novartis, Ryan supports the US HE&OR Immunology, Hepatology, and Dermatology business unit. He works cross-functionally with internal and external stakeholders, working on various parts of a project from concept development to data dissemination dependent on strategic alignment. He is currently involved in multiple projects, including a retrospective claims analysis, an implementation science study, and strategic preparation for an indication launch. In addition, Ryan is also working towards earning a Master's degree in Pharmaceutical Science from the Division of Health Outcomes and Pharmacy Practice at the UT Austin.

# Novartis Pharmaceuticals Corporation/ Thomas Jefferson University, Jefferson College of Population Health



## Fellowship Sites & Preceptors

### Thomas Jefferson University

Vittorio Maio, PharmD, MS, MSPH, Professor and Director, Health Economics and Outcomes Research Fellowship, Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA

### Novartis Pharmaceuticals Corporation

Batul Electricwala, PhD, BPharm, Director, HE&OR and HE&OR Fellowship Director, East Hanover, NJ

## College of Population Health, Thomas Jefferson University

Established in 2008, the Jefferson College of Population Health (JCPH) is one of six colleges that comprise Thomas Jefferson University, founded in 1824 as Jefferson Medical College. JCPH builds upon the 18-year history of Jefferson's Department of Health Policy and specializes in all key areas of population health—public health, health policy, healthcare quality and safety, and applied health economics and outcomes research (AHEOR). The College has one of the oldest and most established outcomes research Fellowship programs in the country. To date, over 50 individuals have completed JCPH Fellowships and have successfully pursued careers in all sectors of the healthcare industry, including government, pharmacy, insurers and consulting.

During the first year, the Fellow will work in JCPH at the University's Philadelphia Center City campus and be assigned to manage specific outcomes research projects. As a member of the JCPH research team, s/he has the opportunity to attend and present at research meetings, journal clubs, Population Health Forums and sponsored educational programs. S/he may also contribute to any one of several graduate level classes taught by JCPH faculty in the College's public health, AHEOR, health policy, healthcare quality and safety, population health intelligence and population health graduate programs. The Fellow will develop writing skills through completion of a writing seminar, peer review of continuing education articles and authorship of manuscripts for publications edited by *American Journal of Medical Quality*, *Population Health Management*, and *Population Health Matters*.

Networking is also an important activity during the first year. The Fellow will interact with decision makers from both within the University and from a broad variety of organizations, including pharmaceutical and device manufacturers, health plans and other health-related employers. The Fellow will regularly meet with JCPH faculty and staff to discuss research projects and academic experiences, and s/he will be assigned a faculty mentor to coach him/her during the first year. Completion of master's level coursework through JCPH is a formal component of this Fellowship and serves to develop the knowledge and skills required for health economics and outcomes research. The Fellow has the option to complete a fully supported graduate Certificate or Master of Science degree program in public health, population health, population health intelligence, health policy or applied health economics and outcomes research.

The second year of training will take place at Novartis, located in East Hanover, New Jersey. During this time, under the guidance of a Novartis preceptor, the Fellow will work directly with the HEOR department at Novartis for a period of one year in order to further their educational objectives by gaining applied experience in health economics and outcomes research. In addition to project work, the Fellow will participate in meetings to share his or her work and further develop networking and presentation skills.

### Eligibility

*Eligible candidates should have an advanced degree in health services research, public health, economics, epidemiology, pharmacy, pharmacy administration or a related discipline. A background in pharmacy or medicine and experience in outcomes research, health economics or another related field of research is preferred. Candidates must have excellent written and verbal communication skills.*

### Information

*For questions or additional information, please contact:*

Adaeze Amaefule, PharmD  
Health Economics & Outcomes Research  
and Medical Access Fellow  
Email: [adaeze.amaefule@jefferson.edu](mailto:adaeze.amaefule@jefferson.edu)

All questions regarding potential visa sponsorship should be directed to the collaborating institution.



**First-Year Fellow:  
Adaeze Amaefule, PharmD**

Adaeze Amaefule is a first-year Health Economics & Outcomes Research (HEOR) Fellow with the Jefferson College of Population Health (JCPH) and Novartis Pharmaceuticals Corporation.

Adaeze received her Doctor of Pharmacy from the University of Maryland, Baltimore (UMB). Her interest in HEOR stems from her background in public health science and passion for improved patient outcomes. While in pharmacy she gained exposure to research, by completing a systematic literature review evaluating the cost-effectiveness of hepatocellular carcinoma treatments. She also worked on a collaborative project with the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) to identify statistical and analytical training tools and resources available to HEOR professionals.

Prior to her fellowship, Adaeze worked in multiple settings such as retail pharmacy, specialty pharmacy, and the pharmaceutical industry. She was a medical affairs intern at Novartis, where she was able to develop proactive disease state slide decks, and work cross-functionally with the HEOR team. Adaeze completed a rotation with Bristol-Myers Squibb's US HEOR team, where she reviewed protocols for unmet need studies. Additionally, she completed a rotation at Xcenda, where she developed new business development proposals and evaluated data visualization tools for field HEOR use.

At JCPH, Adaeze will be involved in a variety of projects, including manuscript writing, protocol development, and outcomes research using insurance claims data, electronic medical records, and survey-based data. In addition, Adaeze is working towards a Master's degree in Applied Health Economics and Outcomes Research. Through the fellowship, Adaeze aims to further develop foundational and advanced skills in HEOR to promote improved patient outcomes and access.



**Second-Year Fellow:  
Jennifer Nguyen, PharmD**

Jennifer Nguyen is the second-year Health Economics & Outcomes Research (HEOR) & Medical Access fellow with the Jefferson College of Population Health (JCPH) and Novartis Pharmaceuticals Corporation.

Jennifer Nguyen received her Doctor of Pharmacy from the University of Houston College of Pharmacy. Prior to the fellowship, Jennifer completed two internships in Janssen's Real World Value & Evidence (HEOR) team where she was involved in the development of a budget impact model, a Tableau dashboard for data visualization of datasets, and conducted real-world evidence analyses.

During her first year of her fellowship at JCPH, Jennifer furthered her training in HEOR through a diverse array of projects analyzing insurance claims data, electronic health record data, and patient-reported outcomes. Jennifer led academic health services research culminating in 3 posters and 1 podium presentation at forums such as the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Academy of Managed Care Pharmacy (AMCP), and American Society of Clinical Oncology (ASCO). For these projects, she participated in the planning and implementation stages of research projects including protocol development, research analysis plan, and project timelines. Jennifer also had the opportunity to become a published author in the American Journal of Medical Quality for her work on improving cancer care through digital health coaching.

During her second year of her fellowship at Novartis, Jennifer supports the US HEOR Neuroscience and Nephrology team by managing research studies through collaboration with cross-functional teams in concept development, protocol review, and strategic planning. Her research consists of retrospective claims database analyses, qualitative research, and economic modelling. Jennifer is also continuing her coursework towards earning a Master's degree in Applied Health Economics and Outcomes Research from JCPH.

# Novartis Pharmaceuticals Corporation/ University of Maryland School of Pharmacy (not recruiting for 2023-2025)



## Fellowship Sites & Preceptors

### University of Maryland School of Pharmacy

Not recruiting for 2023-2025

### Novartis Pharmaceuticals Corporation

Batul Electricwala, PhD, BPharm, Director, HE&OR and HE&OR Fellowship Director, East Hanover, NJ

## The University of Maryland School of Pharmacy

The University of Maryland School of Pharmacy, founded in 1841, is the fourth oldest school of pharmacy in the nation. The School of Pharmacy is one of seven professional schools and a graduate school located at the University of Maryland Baltimore, a thriving center for health services practice and research. Through its education, research and service programs, the School of Pharmacy strives to improve the health and well-being of society by aiding in the discovery, development and optimal use of medicines. One of three departments within the School, the Department of Pharmaceutical Health Services Research (PHSR) aims to improve the health of diverse populations through pharmaceutical health services research, education, service and community outreach.

PHSR scholarship spans the disciplines of behavioral sciences, pharmacoeconomics, pharmacoepidemiology and policy. Fifteen faculty members conduct research sponsored by federal and state governmental agencies, foundations and the pharmaceutical industry. Work clusters around issues inherent in the Department's Centers: The Peter Lamy Center on Drug Therapy and Aging, and the Center on Drugs and Public Policy. Pharmaceutical Research Computing, a third Departmental center, provides computer programming, data management and analytic support to faculty, students and staff.

The Department houses numerous comprehensive databases, including the Chronic Condition Warehouse (CCW) 5% sample of Medicare beneficiaries linked to Part D data; the Medicare Current Beneficiary Survey; Medicaid and MAX data; IQVIA dataset and other proprietary and public data sets.

This two-year Fellowship focuses on the development of research skills relevant to health policy, with a particular focus on pharmaceutical policy. Fellows will spend the first year at the University of Maryland Baltimore honing research and policy skills and the second year at Novartis, where they will apply training and interests in an industry environment. Broad domains of interest include research focusing on medication management and outcomes in geriatric patients suffering multiple chronic illnesses, Medicare policy, long-term-care policy, mental health policy, COVID-19, patient-centered outcomes research and comparative effectiveness research. The successful applicant will work closely with a mentoring team to identify relevant research areas and training opportunities. The unique combination of rigorous academic training with industry experience in the second year will provide the Fellow considerable experience to conduct policy-relevant health services and outcomes research.

### Eligibility

*Eligible candidates should have an advanced degree in health services research, public health, economics, epidemiology, pharmacy, pharmacy administration or a related discipline. A background in pharmacy or medicine and experience in outcomes research, health economics or another related field of research is preferred. Candidates must have excellent written and verbal communication skills.*

### Information

*For questions or additional information, please contact:*

Aaron Carabajal, PharmD  
Health Economics & Outcomes Research and  
Medical Access Fellow  
Email: aaron.carabajal-johnson\_ext@novartis.com

All questions regarding potential visa sponsorship should be directed to the collaborating institution.




**Fellowship Director:  
Batul Electricwala, BS Pharm, PhD**

Batul holds a PhD in Pharmacoeconomics and Health Outcomes from Virginia Commonwealth University and a BS in Pharmacy from Institute of Chemical Technology in India.

Batul joined Novartis as a HEOR Post-Doctoral Fellow in 2016. During her time at Novartis, Batul has supported products through their lifecycle ranging from pipeline through launch and post-launch across various therapeutic areas. She has served as a preceptor to a few HEOR Fellows through the years as well and was appointed as the HEOR Fellowship Director in 2021.

Being a former Novartis Fellow, Batul takes great pride in the Fellowship program; she believes that Novartis, along with its partners, has built a strong foundation for Fellows with an invested team of mentors and preceptors to support Fellows in maximizing their potential.

Batul lives in NJ with her husband, Qusai and almost 1-year-old, Sarah. Besides enjoying her new role as “Mama,” Batul loves traveling, discovering new restaurants, reading, and playing board games.



**Second-Year Fellow:  
Aaron Carabaja, PharmD**

Aaron Carabaja is a second-year Health Economics & Outcomes Research (HEOR) and Medical Access Fellow with Novartis Pharmaceuticals Corporation and the University of Maryland Baltimore.

Aaron received his Doctor of Pharmacy degree from the University of Texas at Austin and brings to the fellowship his valuable experiences from industry, managed care, research, hospital, and community pharmacy. Prior to the fellowship, he supported the Medical Affairs and HEOR teams at AstraZeneca by conducting an analysis of oncology pathway organizations and their effectiveness at reducing healthcare costs while providing optimal treatment strategies for patients. His managed care experience includes monitoring drug usage and cost trends, performing pharmacoeconomic analyses, and synthesizing clinical evidence to support the Department of Defense (DOD) formulary management of SGLT2 inhibitors in the treatment of heart failure. His data analysis and quality improvement experiences include drug utilization reviews of antidiabetic and antihypertensive medications for the DOD Pharmacy & Therapeutics Committee and analyzing retrospective claims data to assess for cost-saving opportunities at the Veteran’s Administration. Additionally, Aaron successfully completed research at UT analyzing polypharmacy in a high-risk elderly population using patient-reported data to assess for potentially inappropriate medication use.

During his first year at the University of Maryland, Aaron focused on further developing his research skills by supporting Dr. Linda Wastila and her team in conducting research pertaining to health policy and outcomes research in vulnerable populations. His projects included analyzing antipsychotic over-use in long-term care facilities at the state, facility, and individual-levels, as well as assessing the impact nursing home facility characteristics and vaccination rates have on COVID-19 vaccination uptake and COVID-19 cases, hospitalizations, and deaths. As a result, Aaron has had the opportunity to present five posters at various research conferences and is in the process of writing four manuscripts for publication at high-impact journals.

In his second year at Novartis, Aaron supports the US HEOR Cardiovascular and Metabolic team. He works cross-functionally with internal and external stakeholders, including academic medical centers, working on various stages in product development, protocol review, and strategic alignment. In addition, Aaron is also working towards earning his Master’s degree in Pharmaceutical Outcomes & Policy with a focus in pharmacoeconomics at the University of Florida.

## Previous Fellows

### **Neetu Agashivala, MS**

Global RWE Head, Cardiovascular Renal Metabolism, Novartis

### **Lauren Bartolome, PharmD**

Director, HEOR I&I, Pfizer, Inc.

### **Kelly Fee Bell, PharmD, MSPhr**

Value Evidence Lead, GlaxoSmithKline

### **William Boyko, PharmD**

Pharmacist Consultant, P&C Pharma

### **Cat Bui, PharmD, PhD**

Director, HEOR, Hematology, AbbVie

### **Scott Bull, PharmD**

Director, Clinical Development, Johnson & Johnson

### **Beilei Cai, PhD, MA**

Senior Director, US HEOR-Oncology, Novartis

### **Jane Chang, MPH**

Senior Director, Value and Evidence, Pfizer, Inc.

### **Michelle Choi, PharmD**

Medical Science Liaison-Immunology, Sanofi

### **Paul C. Cockrum, PharmD, DPh**

North America Director, Oncology HEOR, Ipsen Biopharma

### **Arijita Deb, PhD**

Director, Value Evidence and Outcomes, GlaxoSmithKline

### **Laurence Djatche, PharmD, MS**

Director, HEOR, Endo Pharmaceuticals

### **QuynhChau Doan, PhD, MS, RPh**

Director, External Strategies HEOR, AbbVie

### **Joseph Doyle, MBA**

Pharmacy Manager, Dr. G's Pharmacy

### **Batul Electricwala, PhD**

Director, HEOR, Novartis

### **John Fastenau, PhD, MPH, RPh**

Senior Director, Patient Reported Outcomes, Janssen Pharmaceuticals

### **Feride Frech, PhD, MPH**

Senior Director, HEOR & RWE, Eisai, Inc.

### **Rahul Garg, PhD**

Assistant Professor, Chicago State University

### **Joseph Goble, PharmD, MS**

Director, Value & Evidence Scientific Engagement - Field, Janssen Pharmaceuticals

### **Boris Gorsh, PharmD, MS**

Value Evidence Leader, GlaxoSmithKline

### **Bill Grant, PhD**

Associate Professor of Economics, College of Business, James Madison University

### **Amy Grogg, PharmD**

Strategic Advisor, Vesey Street Capital Partners

### **Kristy Hanson, PharmD, MS**

Scientific Consultant, Value Demonstration, United BioSource Corporation: An Express Scripts Company

### **Peter Hur, PharmD, MBA**

Director, Worldwide HEOR Inflammation and Immunology, Pfizer, Inc.

### **Archi Jackson, PharmD**

President, A&S Healthcare Consulting and Analytics, Inc.

### **Tom Karagiannis, PharmD, MS**

Director, Global Market Access and Pricing, AbbVie

### **Jennifer Kim, PharmD**

Director, Global Pricing and Market Access, AstraZeneca

### **John Kim, PharmD**

Executive Director, Head of Global Market Access, Seagen

### **Nina Kim, PharmD, MS**

Associate Director, Real World Value & Evidence, Oncology, Janssen Pharmaceuticals

### **Yoona Kim, PharmD, PhD**

Co-founder and CEO, Arine

### **John Ko, PharmD, MS**

Senior Director, Value, Evidence & Development Strategy, Beam

### **Amy Law, PharmD, MS**

Director, HEOR, Pfizer, Inc.

### **Junji Lin, PhD**

Associate Director, Jazz Pharmaceuticals

### **Jackie Lu, PharmD, MS**

Executive Director of Marketing, Pacira Pharmaceuticals

### **Mario Luong, PharmD, MPH**

Director of Operations, Optum

**Geneen Graber Maxwell, PharmD**

President and CEO,  
Dr. G's Pharmacy

**Shilpa Mehta, PharmD**

Head of Oncology Marketing - Asia Pacific,  
Merck & Co, Inc

**Patrick Mends, PharmD****Jeannie Menz, PharmD**

Director, Content Development and Training,  
Sandoz

**Laetitia N'Dri, PharmD**

Senior Manager US HEOR,  
Bristol Myers Squibb

**Gilbert C. Ngan, PharmD**

Pharmacist: Part D Benefits Analyst,  
CMS

**Cindy Nguyen, PharmD**

Senior Associate Director, HEOR Value Evidence and  
Outcomes Liaison,  
Boehringer Ingelheim

**Lina Nol-Heiring, BS, MBA**

Therapeutics Sales Specialist,  
LEO Pharma

**Grace Oh, PharmD**

Associate Director, WW Scientific Content and US  
Market Capabilities, Thoracic and Emerging Tumors,  
Bristol Myers Squibb

**Engels Obi, PhD**

Director, Global Outcomes Research and Value  
Evidence Strategy Team Lead,  
Merck

**Jacqueline B. Palmer, PharmD, MBA**

Director, Professional Promotions Marketing,  
Novartis

**Jina Park, PharmD**

Director, Advanced Analytics,  
Komodo Health

**Siyeon Natalie Park, PharmD**

Enterprise Pharmacy - Clinical Carepath,  
Geisinger

**Shivangi Patel, PharmD**

Senior Manager, Patient-Centered Outcomes  
Research, Global Market Access,  
Sarepta Therapeutics

**Hoa T. Pham, PharmD**

Senior Director, Field HEOR,  
Beigene

**Ngan Pham, PharmD**

Senior Consultant,  
IQVIA

**Craig Plauschinat, PharmD, MPH**

Director, HEOR & RWE,  
Eisai, Inc.

**Shibani Pokras, MPH**

Senior Director, Oncology Cell Therapy,  
GlaxoSmithKline

**Karim Prasla, PharmD, MS**

VP, Clinical Outcomes Advanced Analytics and Research,  
Magellan Health Services

**Karina Raimundo, BS Pharmacy, MS**

Director, HEOR,  
Genentech, Inc.

**Swetha Raparla, MS**

Analytics Consultant,  
Cigna

**David Ray, PharmD, MBA, MPH**

Executive Director, Global HEOR,  
Karyopharm Therapeutics, Inc.

**Seon Young Ryu, PharmD**

Mom/Independent Consulting,  
Previously at Genentech

**Rahul Sasané, PhD, MS, BPharm**

Head - Global HEOR-RWE & Reimbursement,  
Cerevel Therapeutics, LLC

**Veronica Sendersky, PharmD**

Managing Director,  
Excellentia Pharma Consulting

**Amishi Shah,**

Associate Director, Oncology Digital Engagement &  
Channel Strategy,  
Merck

**Hemal Shah, PharmD**

President/Founder,  
Value Matters, LLC

**Karishma Shelley, PharmD**

Associate Director, HEOR - US Market, Oncology,  
Bristol Myers Squibb

**Slaven Sikirica, MS**

Senior Director,  
Lexicon Pharmaceuticals, Inc.

**Anh Singhanian, PharmD**

Senior Director, HEOR,  
Turning Point Therapeutics

**Liz Stanley Smart, MPH**

Senior Associate Director, HEOR,  
Boehringer Ingelheim

**Bhavini Patel Srivastava, MS, BS Pharmacy**

Director, HEOR,  
AbbVie

**Kangho Suh, PharmD, PhD, MS**

Assistant Professor,  
University of Pittsburgh

**Dusica Tasic, MS, BS Pharmacy**

Health Economics Manager, Global Marketing,  
GE Healthcare

**Devi Thaker, PharmD, MS**

Director, PharmacoAnalytics,  
Express Scripts

**Melody Tran, PharmD, MS**

Medical Outcomes Liaison,  
Abbott Laboratories

**Yuen Tsang, PharmD, MPH**

Associate Director, Real World Value & Evidence,  
Janssen Pharmaceuticals

**Stuart Turner, MPH**

Executive Director Global Real World Evidence &  
Data Science - Solid Tumors,  
Novartis

**Stefan Varga, PharmD, MSc**

Director, WW HEOR,  
Bristol Myers Squibb

**Ashok Vegesna, PharmD, MS**

Director, National Accounts (Central US),  
Novartis

**Joel Wallace, PharmD, MPH, MBA**

Head, Global HEOR,  
Market Access and Business Strategy,  
Exelixis

**Alexandra Wallem, PharmD,**

Associate Director: Outcomes Liaison,  
Eli Lilly

**Pin Xiang, PharmD**

Director of HEOR Value Demonstration - CNS,  
Boehringer Ingelheim

**Esther Yi, PharmD, MS**

Global Lead, Medical Engagement Analytics,  
Digital Medical Affairs,  
Novartis

**Krista Yokoyama, PharmD**

Senior Manager, Pharmacy Analytics,  
Blue Shield of California

**Jing Yuan, PhD**

Associate Professor,  
Fudan University

# HEOR and Medical Access Fellowship Application Form

Please type or print

Date \_\_\_\_\_

Name: \_\_\_\_\_  
Last First MI

Address: \_\_\_\_\_  
Street City State Zip Code

Phone: \_\_\_\_\_  
Primary Secondary

Email: \_\_\_\_\_

Undergraduate and Graduate Degree(s) (date received or expected):

\_\_\_\_\_  
\_\_\_\_\_

## 2-Year Programs (Preferred Degrees: PharmD, PhD, MS)

Please check any site(s) of interest:

\_\_\_\_\_ Baylor Scott & White Health/The University of Texas at Austin/Novartis Pharmaceuticals Corporation  
\_\_\_\_\_ Thomas Jefferson University College of Population Health/Novartis Pharmaceuticals Corporation

## Application Process (rolling submission, application deadline is October 21<sup>st</sup>, 2022 at 11:59 pm EDT):

To apply, please email [batul.electricwala@novartis.com](mailto:batul.electricwala@novartis.com) and include the following materials:

- Cover Letter
- Application form with first-year fellowship site(s) preference
- CV
- Email of 2 References

If offered an interview, the following documents will be requested:

- 2 Letters of Recommendation (sent via email from references)
- Unofficial Transcript

## Requirements:

Graduate degree in a relevant discipline focused on pharmacy, health services research, health economics, epidemiology, or a related discipline (e.g., PharmD, PhD, MPH, etc.). A background in pharmacy or medicine and experience in outcomes research, health economics, or another related field of research is preferred. Excellent communication skills (oral and written). Demonstrated success in working in teams and independently.

## Please email or send the required application materials to:

Batul Electricwala, PhD, BPharm  
Director, HE&OR and HE&OR Fellowship Director  
Email: [batul.electricwala@novartis.com](mailto:batul.electricwala@novartis.com)

